These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24469001)

  • 1. Abacavir-induced liver toxicity in an HIV-infected patient.
    Di Filippo E; Ripamonti D; Rizzi M
    AIDS; 2014 Feb; 28(4):613. PubMed ID: 24469001
    [No Abstract]   [Full Text] [Related]  

  • 2. Vertigo and abacavir.
    Fantry LE; Staecker H
    AIDS Patient Care STDS; 2002 Jan; 16(1):5-7. PubMed ID: 11839213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large lymphadenopathies complicating the abacavir hypersensitivity reaction.
    García JT; González PR; Hernández-Mora MG; Novoa SR; Quintana FB; Lahoz JG; Vázquez VS
    AIDS; 2007 Oct; 21(16):2254-6. PubMed ID: 18090059
    [No Abstract]   [Full Text] [Related]  

  • 4. Warning against rechallenge with abacavir.
    AIDS Patient Care STDS; 1998 Mar; 12(3):229. PubMed ID: 11361938
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment: Reasons for early abacavir discontinuation in HIV-infected patients.
    Parra-Ruiz J; Martínez-Ramírez M; Muñoz-Medina L; Serrano-Falcón C; Hernández-Quero J
    Ann Pharmacother; 2004 Mar; 38(3):512-3. PubMed ID: 14742830
    [No Abstract]   [Full Text] [Related]  

  • 7. Abacavir-induced liver toxicity.
    Pezzani MD; Resnati C; Di Cristo V; Riva A; Gervasoni C
    Braz J Infect Dis; 2016; 20(5):502-4. PubMed ID: 27054757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziagen (abacavir) approved: caution essential.
    James JS
    AIDS Treat News; 1999 Jan; (No 310):1, 3-6. PubMed ID: 11366148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir and the potential risk of myocardial infarction.
    Cutrell A; Brothers C; Yeo J; Hernandez J; Lapierre D
    Lancet; 2008 Apr; 371(9622):1413. PubMed ID: 18387668
    [No Abstract]   [Full Text] [Related]  

  • 10. Abacavir and increased risk of myocardial infarction.
    Post FA; Campbell LJ
    Lancet; 2008 Sep; 372(9641):803; author reply 804-5. PubMed ID: 18774412
    [No Abstract]   [Full Text] [Related]  

  • 11. Abacavir update.
    Proj Inf Perspect; 1998 Dec; (26):11. PubMed ID: 11366488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abacavir gets green light from FDA advisory board. Food and Drug Administration.
    TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abacavir and increased risk of myocardial infarction.
    Goicoechea M; McCutchan A
    Lancet; 2008 Sep; 372(9641):803-4; author reply 804-5. PubMed ID: 18774413
    [No Abstract]   [Full Text] [Related]  

  • 14. Heart attack risk with abacavir and didanosine.
    AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
    [No Abstract]   [Full Text] [Related]  

  • 15. Management protocol for abacavir-related hypersensitivity reaction.
    Clay PG; Rathbun RC; Slater LN
    Ann Pharmacother; 2000 Feb; 34(2):247-9. PubMed ID: 10676833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abacavir sulfate.
    Porche DJ
    J Assoc Nurses AIDS Care; 2000; 11(6):72-5. PubMed ID: 11082806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir for salvage or intensification.
    Torres G
    GMHC Treat Issues; 1999 Jan; 13(1):4-5. PubMed ID: 11366111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.
    King D; Tomkins S; Waters A; Easterbrook PJ; Thurmond LM; Thorborn DE; Raffi F; Kemeny DM; Vyakarnam A
    J Allergy Clin Immunol; 2005 May; 115(5):1081-7. PubMed ID: 15867870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sweet's syndrome following abacavir therapy.
    Del Giudice P; Vandenbos F; Perrin C; Bernard E; Marq L; Dellamonica P
    J Am Acad Dermatol; 2004 Sep; 51(3):474-5. PubMed ID: 15337997
    [No Abstract]   [Full Text] [Related]  

  • 20. Abacavir at last.
    Gilden D
    GMHC Treat Issues; 1998 Mar; 12(3):9. PubMed ID: 11365394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.